Anygen (KOSDAQ:A196300) - Stock Price, News & Analysis

A196300 Stock Overview

A bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally.

About the company

A196300 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Risk Analysis

Earnings have declined by 0.6% per year over past 5 years

Does not have a meaningful market cap (₩84B)

Shareholders have been diluted in the past year

Does not have meaningful revenue (₩6B)

Anygen Co., Ltd. Competitors

Psomagen

KOSDAQ:A950200

₩79.0b

Clinomics

KOSDAQ:A352770

₩71.4b

Sphere Power

KOSDAQ:A203690

₩86.0b

Cell Biotech

KOSDAQ:A049960

₩86.7b

Price History & Performance

Summary of all time highs, changes and price drops for Anygen
Historical stock prices
Current Share Price	₩14,030.00
52 Week High	₩23,650.00
52 Week Low	₩12,380.00
Beta	0.84
11 Month Change	-0.92%
3 Month Change	-16.98%
1 Year Change	-19.78%
33 Year Change	-2.23%
5 Year Change	18.90%
Change since IPO	11.35%

Recent updates

Does Anygen's (KOSDAQ:196300) Share Price Gain of 86% Match Its Business Performance?

Mar 11

Is Anygen (KOSDAQ:196300) Using Too Much Debt?

Jan 17

Should Anygen (KOSDAQ:196300) Be Disappointed With Their 64% Profit?

Nov 24

Shareholder Returns

	A196300	KR Biotechs	KR Market
7D	-0.7%	-0.4%	0.6%
1Y	-19.8%	15.4%	6.5%

Return vs Industry: A196300 underperformed the KR Biotechs industry which returned 15.4% over the past year.

Return vs Market: A196300 underperformed the KR Market which returned 6.5% over the past year.

Price Volatility

Is A196300's price volatile compared to industry and market?
A196300 volatility
A196300 Average Weekly Movement	4.2%
Biotechs Industry Average Movement	7.4%
Market Average Movement	5.0%
10% most volatile stocks in KR Market	11.2%
10% least volatile stocks in KR Market	2.4%

Stable Share Price: A196300 has not had significant price volatility in the past 3 months.

Volatility Over Time: A196300's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2000	n/a	Jae Il Kim	www.anygen.com

Anygen Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It develops GMP, generic, custom, and catalog peptides, as well as offers other services. The company is also developing AGM-331 targeted for anti-cancer therapy, currently under pre-clinical development phase; AGM-130 indicated for the treatment of triple negative breast cancer, currently under Phase I development phase; AGM-380 indicated for the treatment of viral infection, currently under pre-clinical development phase; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria, currently under pre-clinical development phase.

Anygen Co., Ltd. Fundamentals Summary

How do Anygen's earnings and revenue compare to its market cap?
A196300 fundamental statistics
Market cap	₩84.23b
Earnings (TTM)	-₩9.21b
Revenue (TTM)	₩6.42b

13.1x

P/S Ratio

-9.1x

P/E Ratio

Is A196300 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A196300 income statement (TTM)
Revenue	₩6.42b
Cost of Revenue	₩9.14b
Gross Profit	-₩2.72b
Other Expenses	₩6.49b
Earnings	-₩9.21b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.53k
Gross Margin	-42.32%
Net Profit Margin	-143.38%
Debt/Equity Ratio	73.4%

How did A196300 perform over the long term?

See historical performance and comparison